Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2025-08-07 Major Shareholding Noti…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document is a formal notification of a change in shareholding (flaggningsmeddelande) submitted to the Swedish Financial Supervisory Authority (Finansinspektionen). It details the crossing of a 5% threshold in Oncopeptides AB by Avanza Bank Holding AB. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2025-08-07 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document is a formal notification of a change in shareholding (flaggningsmeddelande) submitted to the Swedish Financial Supervisory Authority (Finansinspektionen). It details the issuer (Oncopeptides AB), the holder (Avanza Bank Holding AB), the transaction date, and the resulting percentage of voting rights and shares. This fits the definition of a Major Shareholding Notification (MRQ), which tracks changes in significant ownership levels.
2025-08-05 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage for an entity ('Avanza Bank Holding AB för Försäkringsaktiebolaget Avanza Pension') in 'Oncopeptides AB'. Specifically, it shows the number of shares and the resulting voting rights percentage after a 'Sälj' (Sale) transaction, crossing a threshold ('Gränsvärde för antal aktier': 5%). This type of filing, which reports changes in significant share ownership levels, directly corresponds to the definition of Major Shareholding Notification (MRQ). The structure and content are typical of regulatory notifications regarding insider or major shareholder transactions.
2025-07-22 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding ('Innehavare', 'Transaktionen: Köp') by an entity (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension) crossing a threshold ('Gränsvärde för antal aktier: 5 %'). It explicitly reports the number of shares held before and after the transaction, and the resulting percentage ownership ('Innehavda aktier: 5,01294 %'). This structure is characteristic of a Major Shareholding Notification, where an investor reports crossing a significant ownership threshold. This aligns with the definition for Major Shareholding Notification (MRQ). The document is short and appears to be a regulatory filing notification rather than a comprehensive report.
2025-07-18 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding ('Innehavare', 'Transaktionen', 'Andel') for a specific instrument ('Aktier') by an entity ('Avanza Bank Holding AB för Försäkringsaktiebolaget Avanza Pension'). The transaction is a 'Köp' (Buy) and the resulting shareholding percentage is reported (4.82075% and 5.1164% of voting rights). This structure, involving reporting changes in ownership that cross specific thresholds (5% mentioned), is characteristic of a Major Shareholding Notification, often referred to as a 'flagging' notification in Nordic markets. This aligns directly with the definition for Major Shareholding Notification (MRQ). The document is short and appears to be a regulatory filing summary, not a comprehensive report.
2025-07-14 Swedish
Oncopeptides announces net sales for Q2 2025
Earnings Release Classification · 1% confidence The document is titled "Oncopeptides announces net sales for Q2 2025" and provides preliminary financial highlights (net sales figures) for the second quarter, explicitly stating this information is released *ahead* of the full interim report. It details key financial metrics and growth rates for the period. This content aligns perfectly with the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). It is not the full Interim Report (IR) itself, as the full report is scheduled for publication later (August 21). Since it is a preliminary announcement of results, ER is the most appropriate classification, rather than RPA (which usually announces the publication of a full report). Q2 2025
2025-07-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.